China saw $28.5 billion invested in its life sciences sector in 2020, which was double the previous year’s amount and sets a five-year high. Partnering activities and IPOs also grew exponentially over the last five years to set records. “After a somewhat down year in 2019 in terms of investment activity in China’s life sciences, 2020 is completely back on track. Venture capital investment, partnering activity and IPOs are literally exploding,” said Greg Scott, founder and chairman of Chinabio Group, at the Chinabio Partnering Forum that opened May 10.

Beigene Ltd.’s PARP inhibitor, pamiparib, won conditional approval from China’s National Medical Products Administration for treating patients with germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer who have been treated with two or more lines of chemotherapy.